Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy

The immune-excluded tumors (IETs) show limited response to current immunotherapy due to intrinsic and adaptive immune resistance. In this study, it is identified that inhibition of transforming growth factor-β (TGF-β) receptor 1 can relieve tumor fibrosis, thus facilitating the recruitment of tumor-...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Mengxue, Wang, Jiaxin, Pan, Jiaxing, Wang, Hui, Huang, Lujia, Hou, Bo, Lai, Yi, Wang, Fengyang, Guan, Qingxiang, Wang, Feng, Xu, Zhiai, Yu, Haijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275881/
https://www.ncbi.nlm.nih.gov/pubmed/37328484
http://dx.doi.org/10.1038/s41467-023-39035-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275881/
https://www.ncbi.nlm.nih.gov/pubmed/37328484
http://dx.doi.org/10.1038/s41467-023-39035-x

Ejemplares similares